H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on uniQure (QURE) to $70 from $25 and keeps a Buy ...

H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently ...

H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years in PlacementTracker's Market ...

H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...

Lexaria Bioscience (NASDAQ:LEXX – Free Report) had its price target trimmed by HC Wainwright from $10.00 to $7.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...

Analysts at HC Wainwright boosted their FY2024 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

Immunic Inc (IMUX) stock saw a modest uptick, ending the day at $0.95 which represents no change from the prior close of of $0.95. The stock opened at $0.98 and touched a low of $0.92 during the day, ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...

https://www.tipranks.com/news/the-fly/optinose-price-target-adjusted-for-stock-split-at-lake-street H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from ...

On Friday, H.C. Wainwright analyst Ed Arce downgraded Galectin Therapeutics (NASDAQ:GALT) stock from Buy to Neutral following the recent clinical trial results. The $70.6 million market cap ...